Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTIF@FRESH vaginal microbiome transplantation study
PACTR202605710907005Phase 2Not yet recruiting
- Sponsor
- Ragon Institute
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of metronidazole, vaginal flora transplant and Placebo-COD Research Private Ltd in bacterial vaginosis (BV) (2 arms), sponsored by Ragon Institute. Primary endpoint: Lactobacillus crispatus dominance within 4 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
metronidazolevaginal flora transplantPlacebo-COD Research Private Ltd
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on PACTR202605710907005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605710907005.